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Granulocyte/macrophage colony-stimulating factor (GM-CSF) promotes the survival, 
proliferation, and differentiation of myeloid lineage cells and regulates chemotaxis and 
adhesion. However, mice in which the genes encoding GM-CSF (
 
Gmcsf
 
) or the 
 
 
 
 common 
subunit of the GM-CSF receptor (
 
 
 
c
 
) are inactivated display normal steady-state 
hematopoiesis. Here, we show that host GM-CSF signaling strongly modulates the ability 
of donor hematopoietic cells to radioprotect lethally irradiated mice. Although bone marrow 
mononuclear cells efficiently rescue 
 
Gmcsf
 
 mutant recipients, fetal liver cells and Sca1
 
 
 
 lin
 
 
 
/dim
 
 
marrow cells are markedly impaired. This defect is partially attributable to accessory cells 
that are more prevalent in bone marrow. In contrast, 
 
Gmcsf
 
-deficient hematopoietic stem 
cells demonstrate normal proliferative potentials. Short-term survival is also impaired in 
irradiated 
 
 
 
c
 
 mutant recipients transplanted with fetal liver or bone marrow. These data 
demonstrate a nonredundant function of GM-CSF in radioprotection by donor hematopoietic 
cells that may prove relevant in clinical transplantation.
 
Hematopoietic stem cell (HSC) transplantation
(HSCT) is a front-line treatment for many
hematologic disorders. Most conditioning regi-
mens administer myeloablative doses of radiation
and/or chemotherapy; however, how the re-
sponse of the host microenvironment influences
donor cell repopulation remains poorly under-
stood. Transplantation protocols utilize bone
marrow, mobilized peripheral blood stem cells
(PBSCs), and umbilical cord blood as sources
of HSCs, and intrinsic variations in HSCs de-
rived from different sources have been reported
previously (1). In clinical practice, the source
of HSCs modulates the duration of posttrans-
plant cytopenia with cytokine-mobilized PBSCs
inducing the most rapid recovery and umbilical
cord blood cells inducing the slowest (2, 3).
GM-CSF promotes the proliferation and
differentiation of myeloid progenitors and
their progeny (4). Although GM-CSF has not
been directly implicated in HSC engraftment,
treatment with recombinant GM-CSF acceler-
ates myeloid recovery in patients undergoing
autologous marrow transplantation (5). More-
over, some patients with posttransplant graft
failure show hematopoietic recovery after
GM-CSF treatment (6). The mechanisms un-
derlying these effects are unknown. Primitive
hematopoietic cells express low to undetectable
levels of the GM-CSF receptor, suggesting that
GM-CSF does not act directly on HSCs, but
rather on lineage-committed cells (7). The
GM-CSF, IL-3, and IL-5 receptors share a
common 
 
 
 
 subunit (
 
 
 
c) that associates with
unique 
 
 
 
 chains to mediate biological re-
sponses to these cytokines (8).
Homozygous 
 
Gmcsf
 
 and 
 
 
 
c
 
 mutant mice
(
 
Gmcsf
 
   
 
 and 
 
 
 
c
 
   
 
)
 
 maintain normal blood
counts, and bone marrow from these animals
restores hematopoiesis in irradiated WT recip-
ients (9–12). The primary abnormality found
in both strains is protein accumulation in the
pulmonary alveoli due to defective macrophage
function (9–12). We previously observed poor
survival of irradiated 
 
Gmcsf
 
   
 
 mice that were
transplanted with fetal liver cells doubly mutant
at the 
 
Gmcsf
 
 and 
 
Nf1
 
 loci (13). Here, we show
that donor accessory cells and host GM-CSF
signaling strongly modulate radioprotection.
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The online version of this article contains supplemental material.
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These data, which define the first essential role for GM-CSF
in hematopoiesis, may prove relevant for enhancing HSCT.
 
RESULTS AND DISCUSSION
Defective radioprotection of 
 
Gmcsf
 
 
 
/
 
 
 
 mice by fetal liver cells
 
Consistent with previous observations, 5 
 
 
 
 10
 
5
 
 
 
Gmcsf
 
   
 
bone marrow cells efficiently repopulated irradiated WT
hosts (9, 12). However, 
 
Gmcsf
 
   
 
 recipients that received ei-
ther 
 
Gmcsf
 
   
 
 or WT bone marrow showed a modest reduc-
tion in survival (Figs. 1 A and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20041504/DC1). In con-
trast, 
 
Gmcsf
 
   
 
 mice that were transplanted with fetal liver
cells demonstrated markedly reduced survival (Fig. 1 A). In
addition, WT mice that received 
 
Gmcsf
 
   
 
 fetal liver cells had
reduced survival compared with the recipients of WT cells
(Fig. 1 B). Recipient mice succumbed 10–30 d after adoptive
transfer with signs of hematopoietic failure (Fig. 1 B). Various
numbers of WT fetal liver cells were injected to observe if the
cell dose influenced survival rates. All WT mice that received
 
 
 
5 
 
 
 
 10
 
5
 
 donor cells survived, whereas transferring up to
2 
 
 
 
 10
 
6
 
 of the same cells did not rescue additional 
 
Gmcsf
 
   
 
animals (Fig. 1 C). These data reveal defective radioprotec-
tion of irradiated 
 
Gmcsf
 
   
 
 mice, which is highly dependent
on whether donor cells are derived from fetal liver or bone
marrow. We also observed an independent effect of donor
fetal liver cell genotype on the survival of WT recipients.
 
WT and 
 
Gmcsf
 
 
 
/
 
 
 
 fetal liver cells show equivalent 
repopulating potentials
 
Next, we performed competitive repopulation experiments
to assess the short- and long-term repopulating abilities of
 
Gmcsf
 
   
 
 and WT hematopoietic cells in recipients of either
genotype. 
 
Gmcsf
 
   
 
 and WT bone marrow cells contributed
equally to hematopoiesis in irradiated recipients (Fig. 2 A).
Because WT fetal liver cells failed to efficiently radioprotect
 
Gmcsf
 
   
 
 recipients (Fig. 1), bone marrow–derived competi-
tors were used to assess the repopulating potential of fetal
liver test cells. 
 
Gmcsf
 
   
 
 fetal liver cells produced similar lev-
els of chimerism as WT cells in recipients assessed 1 and 4
mo after transfer (Fig. 2 B). To exclude the possibility that
GM-CSF production by competitor cells might mask an in-
trinsic defect, we crossed the 
 
Gmcsf
 
   
 
 mutation onto the
B6.BoyJ background and used CD45.1
 
 
 
 bone marrow cells
from these mice as a source of competitors. The repopulat-
ing potentials of 
 
Gmcsf
 
   
 
 and WT fetal liver cells were
equivalent in the absence of GM-CSF production by either
competitor cells or irradiated recipients (Fig. 2 C).
 
Impaired survival of 
 
Gmcsf
 
 
 
/
 
 
 
 recipients injected with bone 
marrow–derived Sca1
 
 
 
 lin
 
 
 
/dim
 
 cells
 
The normal short- and long-term repopulating potentials of
 
Gmcsf
 
   
 
 fetal liver cells suggested that the failure to radio-
 
Figure 1. Radioprotection of WT and 
 
Gmcsf
 
 
 
/
 
 
 
 recipients.
 
 (A) Survival 
rates 1 mo after adoptive transfer in WT (black bars) and 
 
Gmcsf
 
   
 
 (gray bars) 
recipients. Statistically significant differences between WT and 
 
Gmcsf
 
   
 
 
recipients are shown with one (P 
 
 
 
 0.05) or two (P 
 
 
 
 0.01) asterisks. Com-
bining the data for all recipients that received bone marrow cells revealed 
significantly lower survival in 
 
Gmcsf
 
   
 
 (
 
n
 
 
 
 
 
 33) versus WT (
 
n
 
 
 
 
 
 34) hosts 
(P 
 
 
 
 0.009). Similar differences between WT and 
 
Gmcsf
 
   
 
 recipients were 
seen 4 mo after adoptive transfer. (B) Kaplan-Meier analysis of survival in 
recipients of fetal liver cells. The survival of WT mice transplanted with WT 
fetal liver cells was greater than 
 
Gmcsf
 
   
 
 mice that received WT or 
 
Gmcsf
 
   
 
 
donor cells (P 
 
 
 
 0.00001 for both comparisons) and was also significantly 
different than WT hosts injected with 
 
Gmcsf
 
   
 
 fetal liver cells (P 
 
 
 
 0.0001). 
(C) Survival at 1 mo in WT and 
 
Gmcsf
 
   
 
 mice injected with a range of cell 
doses. Pooling the data for the 18 animals of each genotype revealed a 
significant difference in survival (P 
 
 
 
 0.00002). 
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protect 
 
Gmcsf
 
   
 
 recipients might be due to accessory cells
that are present in bone marrow but are deficient in fetal
liver. The Sca1
 
 
 
 lin
 
 
 
/dim
 
 fraction, which is enriched for he-
matopoietic cells with high repopulating potential, com-
prised a similar percentage of cells in 
 
Gmcsf
 
   
 
 and WT mice
(unpublished data). Sca1
 
 
 
 lin
 
 
 
/dim
 
 bone marrow cells were
isolated from WT adult mice and injected into irradiated
WT and 
 
Gmcsf
 
   
 
 recipients (Fig. 3 A). Although 12% of
WT recipients that were transplanted with 1,000 Sca1
 
 
 
lin
 
 
 
/dim
 
 cells survived, increasing the number of cells injected
to 3,000 or more cells rescued 65–70% of irradiated mice
(Fig. 3 B and Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20041504/DC1). In contrast, only 3 out of
32 
 
Gmcsf
 
   
 
 mice that were injected in parallel with 3,000–
20,000 of the same Sca1
 
 
 
 lin
 
 
 
/dim
 
 donor cells survived for
1 mo (P 
 
  
 
0.0005).
Figure 2. Gmcsf /  and WT HSCs show equivalent repopulating 
potentials. (A and B) WT test cells transplanted into WT recipients are 
shown as a solid black line, Gmcsf    test cells transplanted into WT 
recipients are shown as a dotted black line, WT test cells transplanted into 
Gmcsf    hosts are shown as a solid gray line, and Gmcsf    test cells 
transplanted into Gmcsf    recipients are shown as a dotted gray line. 
Error bars represent standard deviations. (A) Bone marrow mononuclear 
cells from WT and Gmcsf    mice at the designated doses were trans-
planted in conjunction with 5   105 whole bone marrow cells from WT 
B6.BoyJ (CD45.1 ) mice. Levels of donor (CD45.2) chimerism are shown 
1 mo after transplant. (B) Levels of CD45.2 chimerism in recipients trans-
planted with various numbers of WT or Gmcsf    donor cells that were 
mixed with 5   105 WT CD45.1  bone marrow competitors. (C) Levels of 
CD45.2 chimerism in recipients transplanted with various numbers of 
Gmcsf    fetal liver cells that were mixed with either WT or Gmcsf    
CD45.1  bone marrow competitors. The solid black line represents WT 
hosts receiving WT competitor cells, the dotted black line shows WT hosts 
receiving Gmcsf    competitor cells, the solid gray line shows Gmcsf    
hosts receiving WT competitor cells, and the dotted gray line shows 
Gmcsf    hosts receiving Gmcsf    competitor cells. The percentages of 
donor cell chimerism were stable at 4 mo (not depicted).
Figure 3. Hematopoietic reconstitution of wild-type and Gmcsf /  
recipients transplanted with Sca1  lin /dim bone marrow cells. (A, left) 
A forward and side scatter plot of bone marrow cells after MACS selection 
of Sca1  cells and (right) the sorting gate used to isolate the Sca1  lin /dim 
fraction for adoptive transfer (boxed area, 11.35% of total cells). (B) Survival 
of irradiated WT (black bars) and Gmcsf    (gray bars) recipients 1 mo af-
ter adoptive transfer of the indicated number of WT Sca1  lin /dim bone 
marrow cells is shown. Significant differences between WT and Gmcsf    
recipients are shown with one (P   0.05) or two (P   0.01) asterisks.GM-CSF SIGNALING MODULATES RADIOPROTECTION | Katsumoto et al. 856
Irradiated accessory cells and exogenous GM-CSF enhance 
the survival of Gmcsf /  recipients
Because the percentage of cells expressing the Mac1 integrin
complex was much lower in fetal liver versus bone marrow
( 5 versus  45%; unpublished data), we asked if accessory
function provided by bone marrow–derived Mac1  cells
contributes to radioprotection. To test this hypothesis, he-
matopoietic subpopulations were isolated from Gmcsf   
bone marrow by cell sorting, irradiated with 1,800 cGy,
mixed with fetal liver cells, and transferred into irradi-
ated recipients. Table I and Fig. S3 (available at http://
www.jem.org/cgi/content/full/jem.20041504/DC1) dis-
play the results of two independent experiments. Consistent
with our previous data, the same WT donor fetal liver cells
rescued 8 out of 9 WT recipients, but only 1 out of 11
Gmcsf    mice. Irradiated Sca1  Lin  Gmcsf    bone marrow
cells did not rescue irradiated hosts (unpublished data). How-
ever, cotransplanting 2   105 or 106 irradiated Sca1  Lin 
Gmcsf    cells with 2   106 WT fetal liver cells produced du-
rable engraftment in 8 out of 11 Gmcsf    recipients. Further-
more, coinjecting 106 irradiated Mac1  cells derived from
Gmcsf    bone marrow with fetal liver cells also rescued he-
matopoiesis in all 10 Gmcsf    recipients (Table I). These
studies identify an accessory function within the differenti-
ated fraction of bone marrow cells that facilitates the ability of
fetal liver cells to radioprotect Gmcsf    mice.
We also asked if irradiated Gmcsf    accessory cells could
restore the ability of bone marrow–derived Sca1  lin /dim
cells to radioprotect Gmcsf    recipients. In these studies, irra-
diated Gmcsf    bone marrow cells (5   106 per mouse) were
coinjected with 7,500 WT or Gmcsf    Sca1  lin /dim cells.
Gmcsf    recipients that received Sca1  lin /dim cells of either
genotype died with graft failure within 14 d of transfer (n  
10). In contrast, 6 out of 10 animals that received Sca1  lin /dim
cells with irradiated bone marrow cells survived for  3 mo
(Fig. S2), including 3 out of 5 transplanted with Gmcsf   
Sca1  lin /dim cells. These data confirm the existence of ac-
cessory cells in murine bone marrow that cooperate with
Sca1  lin /dim donor cells to radioprotect irradiated Gmcsf   
mice. Furthermore, this accessory cell population achieves
rescue through a mechanism that appears to be independent
of both proliferation and GM-CSF production.
We administered a supernatant prepared from B16 mela-
noma cells that had been engineered to produce murine
GM-CSF (500  l of supernatant containing  73 ng/ml of
GM-CSF) or a control B16 supernatant to ask if exogenous GM-
CSF could improve the survival of Gmcsf    recipients trans-
planted with fetal liver cells. All mice were injected intraperi-
toneally on the day before adoptive transfer, the day they were
irradiated and transplanted with 106 WT fetal liver cells, and
on the day after transfer. In the first experiment, the mice were
treated daily for the next week. In the other, a single additional
injection of B16/GM-CSF or control parental B16 superna-
tant was administered 1 wk after adoptive transfer. In these
two experiments, only one out of eight Gmcsf    recipients
that were injected with the control supernatant survived for
14 d after adoptive transfer, whereas six out of eight animals
that received B16/GM-CSF supernatant were alive after 1 mo.
Defective survival of irradiated  c    recipients
Our studies of Gmcsf    mice suggested that signaling
through the  c chain in recipient stromal cells modulates the
ability of donor cells to rescue short-term hematopoiesis. To
further investigate this idea, we transferred WT bone mar-
row or fetal liver cells (5   105 per recipient) into irradiated
 c    or control mice.  c    mice that received WT fetal
liver cells showed impaired survival that was similar to
Gmcsf    hosts (Fig. 4 and Fig. S4, available at http://www.
jem.org/cgi/content/full/jem.20041504/DC1). However,
this deficit was not restricted to donor fetal liver cells, but
was also seen in recipients that were transplanted with WT
bone marrow.
These studies identify a nonredundant role of GM-CSF
signaling in radioprotection that is strongly modulated by
donor accessory cells. The high rate of lethality in Gmcsf   
or  c    recipients transplanted with fetal liver cells and the
ability of exogenous GM-CSF to improve survival in
Gmcsf    mice revealed a major influence of host genotype
in radioprotection. Similarly, depleting accessory cells from
Table I. Effect of irradiated Gmcsf    bone marrow cells on 
fetal liver cell engraftment
Recipient
genotype
WT
fetal liver
Irradiated/Gmcsf / 
bone marrow Survival/total p-value
Gmcsf    1/11
WT    8/9  0.0005
Gmcsf   Lin  8/11 0.001
Gmcsf   Mac1  10/10  0.0005
WT C57BL/6 mice received 2   106 fetal liver cells with or without Lin  or Mac1  
Gmcsf    marrow cells that were radiated with 1,800 cGy before injection. The
p-values indicate differences in survival at 1 mo between Gmcsf    recipients that 
received fetal liver cells only and the other groups (unpaired Student’s t test).
Figure 4. Radioprotection of  c mutant mice. WT bone marrow or 
fetal liver efficiently repopulated WT recipients (black bars). In contrast, 
 c    recipients (gray bars) that were transplanted with WT donor cells 
showed reduced survival. Significant differences are shown with two 
asterisks (P   0.01).JEM VOL. 201, March 21, 2005 857
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donor bone marrow or adding these cells to fetal liver mod-
ulated the survival of Gmcsf    recipients, demonstrating a
strong and independent effect of accessory cells in facilitating
engraftment. Although we examined short-term radiopro-
tection as the primary endpoint, Kaplan-Meier survival anal-
ysis of recipients observed beyond 1 mo gave similar results
(Figs. S1–S4). Together, our data indicate a complex inter-
action between host GM-CSF signaling and donor accessory
cells in radioprotection and underscore the importance of
both factors in this phenotype.
Myelo-erythroid and common myeloid progenitors are
responsible for radioprotection, whereas long-term reconsti-
tution requires engraftment by HSCs (14). However, my-
elo-erythroid progenitors, common myeloid progenitors,
and HSCs do not express the GM-CSF receptor (15) and  c
mutant cells efficiently repopulate wild-type recipients (10, 11).
These data infer that GM-CSF facilitates radioprotection by
a mechanism that does not require direct effects on repopu-
lating donor cells. GM-CSF is concentrated in the bone
marrow microenvironment where it is membrane anchored
or immobilized within the extracellular matrix (16), which
allows it to signal through receptors on target cells in a spa-
tially localized manner. Irradiation induces GM-CSF pro-
duction by cultured bone marrow stromal cells (17) and by
stromal and endothelial cell lines (18). Furthermore, whereas
GM-CSF mRNA levels are up-regulated within the bone
marrow and spleen of mice 2 d after irradiation, there is no
increase in serum levels (19). These data support the idea
that GM-CSF is produced by stromal cells in response to ra-
diation and acts locally. Although it is not known how GM-
CSF signaling in recipient mice enhances radioprotection,
GM-CSF has antiapoptotic effects in some cell types (20, 21).
Alternatively, the observation that Mac1  cells from Gmcsf   
mice demonstrate defective phagocytosis of apoptotic cells in
vivo (22) suggests that impaired clearance of dead or dying
cells within the microenvironment might contribute to the
radiation sensitivity of Gmcsf and  c mutant mice.
Our finding that donor accessory cells facilitate hemato-
poietic recovery after irradiation is consistent with a report
that examined engraftment of nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice by hu-
man Lin CD34 CD38  cord blood cells (23). Furthermore,
CD26 expression on donor hematopoietic cells reduces en-
graftment efficiency and it has been suggested that accessory
cells partially rescue this phenotype (24). Accessory cells may
also modulate the effects of other molecules such as CXCR4
on homing and engraftment. In studies using fetal liver do-
nor cells, we found that a relevant accessory population is
contained within the Mac1  fraction. However, we have
not formally excluded the possibility that other cell fractions
contribute to radioprotection. The ability of Gmcsf    bone
marrow–derived accessory cells to improve the survival of
Gmcsf    mice transplanted with fetal liver or with bone
marrow–derived Sca1  lin /dim cells is consistent with the
observation that these recipients are efficiently rescued by
Gmcsf    bone marrow. However, it is intriguing that this
accessory activity is radioresistant, particularly because the
same populations are present in recipient bone marrow. The
apparent paradox might be explained by differential effects of
in vivo versus ex vivo radiation on accessory function, or
may be modulated by the number of accessory cells injected.
Consistent with the latter possibility, WT donor fetal liver
cells provided better radioprotection than Gmcsf    fetal liver
cells but had equivalent long-term repopulating potential.
These data suggest that GM-CSF production by donor ac-
cessory cells becomes important at reduced cell numbers.
Limit dilution experiments comparing WT versus Gmcsf   
accessory cells are required to definitively address this issue.
Potential mechanisms through which irradiated donor acces-
sory cells might facilitate radioprotection include guiding cells
with short- and long-term repopulating potential to appropri-
ate niches, facilitating adherence, and/or clearing apoptotic
cells and debris from the irradiated host microenvironment.
Our data raise the possibility that a relative deficit in ac-
cessory cell function contributes to delayed engraftment in
patients who are transplanted with umbilical cord blood (2, 3).
Recombinant GM-CSF has not proven superior to G-CSF
in recipients of mobilized PBSCs and is no longer used in
most transplant centers because of a higher incidence of side
effects. However, investigating how GM-CSF and other
growth factors modulate the responses of host bone marrow
microenvironment to irradiation and how cytokines act
upon accessory cells that are infused could uncover strategies
for enhancing the safety and efficacy of HSCT. Further-
more, manipulating donor cell populations ex vivo to isolate
cells with high repopulating potential could paradoxically in-
crease the risk of graft failure if critical accessory cell popula-
tions are eliminated during processing.
MATERIALS AND METHODS
Mice. Gmcsf and  c mutant mice (9, 10) were backcrossed six generations
onto the C57BL/6 strain (CD45.2 ). WT C57BL/6 mice (CD45.2 ) and
congenic B6.SJL-PtrcaPep3b/BoyJ (B6.BoyJ) mice (CD45.1 ) were pur-
chased from The Jackson Laboratory. The University of California San
Franscisco Committee on Animal Research approved the experimental
procedures.
Hematopoietic cells.  Pregnant WT, Gmcsf   , and  c    females were
killed by CO2 inhalation at E14 and fetal liver cells were prepared as de-
scribed previously (13). Bone marrow cells were collected by flushing tibias
with IMDM supplemented with 20% FCS (Hyclone Laboratories).
Genotyping. Mice were genotyped at the Gmcsf and  c loci by Southern
blotting as described previously (9, 10). PCR was also used to genotype
Gmcsf mice (protocol available upon request).
Adoptive transfer and competitive repopulation. Recipients were ir-
radiated with a single fraction of 850 cGy, which was uniformly lethal in
the absence of donor cells. Fetal liver or bone marrow cells were injected
into the dorsal tail vein of 10–12-wk-old recipients after irradiation. Short-
term engraftment was defined as survival for 30 d after adoptive transfer,
and radioprotection was defined as survival beyond the 12–18 d critical
window of bone marrow failure. Competitive repopulation experiments
were performed essentially as described by coinjecting CD45.2  test cells
with CD45.1  competitors (25). Recipients received prophylactic oral anti-
biotics for 3 wk after irradiation.GM-CSF SIGNALING MODULATES RADIOPROTECTION | Katsumoto et al. 858
Flow cytometry.  Blood leukocytes were analyzed for chimerism using
antibodies to CD45.1-PE and CD45.2-FITC. In some experiments, cells
were counterstained with the lineage specific antibodies CD3-TC, B220-TC,
Gr1-PE, and Mac1-PE (BD Biosciences). CD45 chimerism analysis was
performed by flow cytometry with 10,000 events collected using a FAC-
Scan (Becton Dickinson) and analyzed using CELLQuest software. For the
Sca1  lin /dim sort, cells were stained with the following mix of antibodies:
Sca-1–FITC, B220-PE, CD3-PE, Mac1-PE, TER119-PE, and Gr-1–PE.
The cells were labeled with anti-FITC MACS beads to select for Sca1  cells
on an autoMACS instrument and the Sca-1–enriched product was sorted
using a BD FACS Vantage SE cell sorter. A rectangular sorting gate was
drawn around the FITC  PE /dim population and these cells were collected
for injection (Fig. 3 A).
Online supplemental material. Kaplan-Meier analyses of data shown in
Figs. 1 A, 3 B, and 4 and in Table I are presented as Figs. S1–S4. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20041504/DC1.
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